Nautilus Biotechnology, Inc. is a development-stage life sciences company focused on creating a platform technology to quantify and analyze the human proteome. The company develops a measurement method called Iterative Mapping, which analyzes single, intact protein molecules at scale to enable broadscale proteome analysis and targeted proteoform analysis. Its primary product is the Nautilus Voyager platform, an integrated system that combines nanofabricated protein arrays, affinity reagent probing, advanced optics and fluidics, and machine learning-based analysis. The platform is designed to provide high reproducibility and depth in protein measurement, addressing limitations of existing mass spectrometry and affinity-based technologies. Nautilus serves researchers in drug discovery, biomarker development, and precision medicine. The company was founded in 2016 and completed a business combination with ARYA Sciences Acquisition Corp III in June 2021.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage nautilus.bio
Sector Healthcare IR page investors.nautilus.bio
Tags
proteomics, single-molecule analysis, protein arrays, biomarker discovery, precision medicine, nanofabrication, machine learning, life sciences research, Nautilus Voyager, Iterative Mapping
Press page —

Metrics

Valuation  
Market cap $ 180.807M
Market cap (USD) $ 180.807M
P/E -3.09
PEG —
P/BV 1.55
P/S —
P/OCF -3.45
P/FCF -3.28
Dividend yield —
Turnover / mcap —
Returns  
ROE -32.3%
ROI -34.5%
ROIC -29.4%
Profit margin —
Growth  
Revenue growing —
Profits growing Yes
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 21
Quality score -41.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Assets 191.112M 242.743M 305.565M 350.052M 398.45M 85.011M
Net profit -59.001M -70.78M -63.675M -57.924M -50.315M -15.619M
Free cash flow -51.973M -61.267M -54.153M -48.13M -41.51M -14.917M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 1.95 1.68 2.99 1.8 5.18 10.85
Price performance 12m 0.16 -0.44 0.66 -0.65 -0.52 —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — 4.78M 30M 30.3M 34.6M 30.5M 30M
Cash and deposits (USD) 595,000 1M 186M 115M 19.4M 27.6M 12.4M
Right-of-use assets (USD) — 4.84M 29.4M 28.9M 32.6M 28.3M 27.8M
Cash flow detail
Operating cash flow (USD) — -14M -39.2M -45.8M -51.7M -59.1M -50.7M
Purchases of property, plant and equipment (USD) — -921,000 -2.27M -2.32M -2.44M -2.12M -1.28M
Change in payables (cash effect) (USD) — 123,000 1.26M -561,000 393,000 -578,000 -69,000
Share-based compensation (USD) — 369,000 7.93M 10.4M 12.1M 12.7M 6.84M
Free cash flow (OCF - PPE - intangibles) (USD) — -14.9M -41.5M -48.1M -54.2M -61.3M -52M
Income detail
Research and development expense (USD) — 12.4M 29.4M 37.7M 47.3M 50.5M 41.1M
↳ 5y CAGR +27.0%
Total comprehensive income (USD) — -15.6M -50.5M -59.6M -62.1M -70.5M -58.8M
Comprehensive income to owners (USD) — -15.6M -50.5M -59.6M -62.1M -70.5M -58.8M
Reported Aug 10, 2021 Feb 24, 2022 Feb 24, 2022 Feb 23, 2023 Feb 28, 2024 Feb 27, 2025 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... Show more

NecessaryAlways Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytics

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

Advertisement

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

Uncategorized

Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.

Reject All Save My Preferences Accept All

Powered by Cookieyes logo

Skip to content

News Release Details

Nautilus to Measure Proteoforms Driving Alzheimer’s Disease and Cancer in ARPA-H-Funded SEEDS Consortium

Oct 27, 2026

PDF Version

Nautilus expects to receive up to $6 million to bring its Voyager™ Platform to a multidisciplinary team integrating protein science, AI, and computational modeling to develop new diagnostics and therapeutics

SEATTLE, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering intact, single-molecule proteomics approaches, today announced its participation in SEEDS (Sequence-to-disease: Environment-aware Ensembles of Disordered proteins at Scale), a four-year, multi-center research consortium awarded up to $51.7 million by the Advanced Research Projects Agency for Health (ARPA-H). The consortium, which is co-led by the Buck Institute for Research on Aging and Georgetown University, aims to predict how disease-causing proteins misfold before irreversible damage occurs, and to use those predictions to develop new ways of detecting, slowing, and treating neurodegenerative diseases and cancer. Nautilus expects to receive up to $6 million over the duration of the program to deploy its Voyager Platform to measure proteoforms – the distinct versions of proteins that drive function – from model systems, disease tissues, and biofluids, starting with Alzheimer’s disease and Ewing sarcoma.

“The field knows more today about the downstream effects of protein misfolding than the upstream molecular causes. Nautilus’ Iterative Mapping method is expected to provide an important tool to help us quantify the diverse proteoforms that may drive misfolding in the first place. Within SEEDS, we will apply the method to diseases where early intervention is critical,” said Priyanka Joshi, Ph.D., Assistant Professor in the Department of Biochemistry and Molecular & Cellular Biology at Georgetown University School of Medicine and SEEDS co-lead.

The genesis of pathologies such as Alzheimer’s disease and cancer often lies in protein dysregulation, misfolding, and aggregation. SEEDS seeks to understand and predict the behavior of intrinsically disordered proteins implicated in these diseases. As many as half of human proteins may have intrinsically disordered regions whose shapes are constantly shifting. Because they lack the stable shapes and binding pockets that most drugs are designed to fit, they have been hard to study and have long been considered “undruggable.” Some of these protein shapes are prone to aggregation, leading to irreversible damage. Today, most treatments arrive only after that point, making earlier detection and intervention essential. SEEDS aims to address this challenge by developing diagnostics and therapeutics that enable earlier intervention. SEEDS is part of ARPA-H’s BIOmolecular Grammar for protein Aggregation Modulation and Intervention (BIOGAMI) program, which focuses on the earliest stages of protein dysfunction, and is led by ARPA-H Program Manager Shannon Greene, Ph.D.

“Understanding how protein folding changes patterns that drive disease has been critical in our field,” said Chuankai (Kai) Zhou, Ph.D., Principal Investigator at the Buck Institute for Research on Aging and SEEDS co-lead. “The Nautilus Voyager™ Platform is expected to give us a way to quantify how proteoforms contribute to distinct conformational states at high resolution, enabling us to determine how we might preempt disease progression before irreversible damage occurs.”

Within SEEDS, the Nautilus work under the program will support the study of proteoforms of tau and EWS::FLI1, proteins implicated in Alzheimer’s disease and Ewing sarcoma, respectively, and is anticipated to extend to a larger set of intrinsically disordered proteins. The Voyager Platform is designed to analyze millions to billions of intact proteins independently and simultaneously at massive scale to quantify the complex dynamics of the proteoform landscape across disease processes. The large data corpus generated from these studies is expected to be used to train AI models to predict how proteoforms push a protein toward aggregation. SEEDS researchers may be able to use those predictions to design new diagnostics and therapeutics.

Nautilus’ participation in SEEDS builds on work already underway:

  • A Voyager Platform field-evaluation unit at the Buck Institute for Research on Aging generating tau proteoform data since early 2025.

  • Initiation of the Iterative Mapping Early Access Program earlier this year to enable broader access to Iterative Mapping of proteoforms ahead of the planned Voyager Platform shipment in mid-2027.

  • Recent validation of the proprietary Iterative Mapping method in a peer-reviewed Nature Methods publication.

  • A collaboration with the Michael J. Fox Foundation and Weill Cornell Medicine-Qatar, supported by a foundation research grant, to develop a proteoform assay for alpha-synuclein, the protein implicated in Parkinson’s disease.

SEEDS is the first application of Iterative Mapping to a pediatric cancer, Ewing sarcoma, and Nautilus plans to add proteoform assays on a continuing basis, with approximately 20 expected by mid-2028.

“We are excited to bring Iterative Mapping of proteoforms to this ARPA-H-supported effort to help define the critical link between proteoforms, protein misfolding, and disease,” said Parag Mallick, Ph.D., Co-founder and Chief Scientist at Nautilus. “We believe that the highly differentiated data from the Nautilus Voyager Platform could unlock a new generation of proteoform-enabled diagnostics and therapeutics.”

SEEDS is funded, in part, by the Advanced Research Projects Agency for Health (ARPA-H). The views and conclusions contained in this document are those of the authors and should not be interpreted as representing the official policies, either expressed or implied, of the U.S. Government.

About the Nautilus Voyager™ Platform The Voyager Platform employs Nautilus’ proprietary Iterative Mapping approach, which is designed to enable rapid measurement of intact, single-molecule proteins and proteoforms in a single, sample-to-answer workflow any lab can run. The platform’s flow cells are designed to accommodate up to 10 billion intact protein molecules, enabling measurement across an exceptionally wide dynamic range. Iterative Mapping independently probes single protein molecules across tens to hundreds of cycles, recording unique binding patterns for each individual molecule. Machine learning algorithms then convert the resulting probe-binding patterns into confident protein and proteoform quantifications, producing the structured, reproducible data required to train models on functional biology. Once analysis is complete, single-molecule counts are made available for download and further visualization. The Voyager instrument is designed for operational simplicity and standard lab benchtop placement, with a guided touchscreen user interface and minimal facility requirements, without need for bespoke gas or fluidic connections.

About Nautilus Biotechnology, Inc. With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company advancing Voyager, a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.

Special Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws. Forward-looking statements in this press release include, but are not limited to, statements regarding Nautilus’ expectations with respect to the amount and timing of any funding that Nautilus may receive, the anticipated scope, activities and outcomes of the SEEDS research program, the planned timing of the Voyager Platform shipment, the expected number and timing of additional proteoform assays, the potential of its platform technology, its future products, their functionality and performance or their applicability in biological research and in potentially enabling new diagnostics and therapies. These statements are based on numerous assumptions concerning the development of Nautilus’ products, target markets, and other current and emerging proteomics technologies, and involve substantial risks, uncertainties and other factors that may cause actual results to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that could materially affect the accuracy of Nautilus’ assumptions and its ability to achieve the forward-looking statements set forth in this press release include (without limitation) the following: Nautilus’ product platform is not yet commercially available and remains subject to scientific and technical development, which is inherently challenging and difficult to predict; we may experience material delays as a result of unanticipated events; we cannot provide any guarantee or assurance with respect to the outcome of our development, collaboration, and commercialization initiatives or with respect to their associated timelines. For a more detailed description of additional risks and uncertainties facing Nautilus and its development efforts, investors should refer to the information under the caption “Risk Factors” in our Annual Report on Form 10-K as well as in our Quarterly Report on Form 10-Q to be filed for the quarter ended September 30, 2026 and our other filings with the SEC. The forward-looking statements in this press release are as of the date of this press release. Except as otherwise required by applicable law, Nautilus disclaims any duty to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Disclosure Information Nautilus uses filings with the Securities and Exchange Commission, its website (www.nautilus.bio), press releases, public conference calls, public webcasts, and its social media accounts as means of disclosing material non-public information and for complying with Regulation FD. Therefore, Nautilus encourages investors, the media, and others interested in Nautilus to review the information it makes public in these locations, as such information could be deemed to be material information.

Media Contact [email protected]

Investor Contact [email protected]

Stay up-to-date on all things Nautilus

Subscribe to our investor alerts

Subscribe

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... Show more

NecessaryAlways Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytics

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

Advertisement

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

Uncategorized

Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.

Reject All Save My Preferences Accept All

Powered by Cookieyes logo

Skip to content

News Release Details

Nautilus Biotechnology Reports Third Quarter 2026 Financial Results

Oct 27, 2026

PDF Version

SEATTLE, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2026.

Third Quarter 2026 Business Highlights

  • Published a peer-reviewed paper in Nature Methods showing how Iterative Mapping reveals the proteoforms underlying biology and disease, with potential to yield new biomarkers and drug targets.

  • Shared first development data on oncology proteoform assays, including AKT1, at World HUPO 2026, showing a performance profile matching Tau and supporting platform extensibility.

  • Advanced the proteoform pipeline needed to deliver twenty assays planned through mid-2028.

  • Subsequent to quarter end, announced participation in SEEDS, a four-year, multi-center research consortium funded by ARPA-H, with Nautilus expecting to receive up to $6 million to deploy its Voyager PlatformTM to measure proteoforms driving Alzheimer’s disease and cancer.

“The third quarter marked an important step in demonstrating the power and scalability of Iterative Mapping on our Voyager platform,” said Sujal Patel, CEO of Nautilus Biotechnology. “Our seminal publication in Nature Methods highlights the unique biological insights that our technology can deliver. In addition, our proteoform expansion initiative is on-track, with early oncology assay results that demonstrate the performance we established with Tau is repeatable across additional targets. This repeatability is fundamental to our strategy of building a broad portfolio of proteoform assays, and the progress we are seeing reinforces our confidence in our technology, our development roadmap, and our planned instrument availability in the middle of 2027.”

Third Quarter 2026 Financial Results

Revenue was $0.2 million for the third quarter of 2026, primarily driven by grant revenue from the Company’s activities related to the grant awarded from The Michael J. Fox Foundation during the period, and service revenue for the sales of services under the Iterative Mapping Early Access Program.

Operating expenses were $16.9 million for the third quarter of 2026, a $1.5 million or 10% increase compared to $15.5 million for the corresponding prior year period. The increase in operating expenses is attributable to higher laboratory and professional services and higher salaries and related benefits expense, partially offset by lower facilities expenses.

Net loss was $15.6 million for the third quarter of 2026, as compared to the net loss of $13.6 million for the corresponding prior year period.

Cash, cash equivalents, and investments were $114.3 million as of September 30, 2026.

Webcast and Conference Call Information

Nautilus will host a conference call to discuss the third quarter 2026 financial results, business developments and outlook before market open on Tuesday, October 27, 2026, at 5:30 AM Pacific Time / 8:30 AM Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.nautilus.bio.

About Nautilus Biotechnology, Inc.

With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio

Special Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws. Forward-looking statements in this press release include, but are not limited to, statements regarding Nautilus’ expectations regarding the company’s business operations, financial performance and results of operations; expectations regarding operating expenses and cash runway, including any impact thereon from our reallocation of resources; expectations with respect to any revenue timing or projections; expectations with respect to the development required for and the timing of the launch of the Nautilus VoyagerTM platform, our proteoform applications roadmap and full commercial availability of our proteoform and/or broadscale products and/or services; the functionality and performance of the Nautilus Voyager platform, its potential impact on providing proteome or proteoform access, pharmaceutical development and drug discovery, expanding research horizons, and enabling scientific explorations and discovery; expectations regarding platform specifications required by potential customers and partners and the timeline for adoption of the Nautilus Voyager platform by researchers; and the present and future capabilities and limitations of emerging proteomics technologies. These statements are based on numerous assumptions concerning the development of Nautilus’ products, target markets, and other current and emerging proteomics technologies, and involve substantial risks, uncertainties and other factors that may cause actual results to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that could materially affect the accuracy of Nautilus’ assumptions and its ability to achieve the forward-looking statements set forth in this press release include (without limitation) the following: the Nautilus Voyager product platform is not yet commercially available and remains subject to significant scientific and technical development, which is inherently challenging and difficult to predict, particularly with respect to highly novel and complex products such as those being developed by Nautilus. Even if our development efforts are successful, our product platform will require substantial validation of its functionality and utility in life science research. In the course of Nautilus’ scientific and technical development and associated product validation and commercialization, we may experience material delays as a result of unanticipated events. We cannot provide any guarantee or assurance with respect to the outcome of our development, collaboration, and commercialization initiatives or with respect to their associated timelines, or that we will receive the full amount of the SEEDS funding, which may be reduced, delayed or terminated. For a more detailed description of additional risks and uncertainties facing Nautilus and its development efforts, investors should refer to the information under the caption “Risk Factors” in our Annual Report on Form 10-K as well as in our Quarterly Report on Form 10-Q to be filed for the quarter ended September 30, 2026 and our other filings with the SEC. The forward-looking statements in this press release are as of the date of this press release. Except as otherwise required by applicable law, Nautilus disclaims any duty to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Disclosure Information

Nautilus uses filings with the Securities and Exchange Commission, its website (www.nautilus.bio), press releases, public conference calls, public webcasts, and its social media accounts as means of disclosing material non-public information and for complying with Regulation FD. Therefore, Nautilus encourages investors, the media, and others interested in Nautilus to review the information it makes public in these locations, as such information could be deemed to be material information.

Media Contact[email protected]

Investor Contact[email protected]

| Nautilus Biotechnology, Inc. |

| Condensed Consolidated Balance Sheets |

| As of September 30, 2026 and December 31, 2025 (Unaudited) |

| | | | |

| (in thousands) | September 30, 2026 | | December 31, 2025 |

| Assets | | | | | | | |

| Current assets: | | | | | | | |

| Cash and cash equivalents | $ | 10,467 | | | $ | 12,388 | |

| Short-term investments | | 76,109 | | | | 91,018 | |

| Prepaid expenses and other current assets | | 3,661 | | | | 2,557 | |

| Total current assets | | 90,237 | | | | 105,963 | |

| Property and equipment, net | | 5,268 | | | | 3,457 | |

| Operating lease right-of-use assets | | 24,592 | | | | 27,773 | |

| Long-term investments | | 27,767 | | | | 52,739 | |

| Other long-term assets | | 1,060 | | | | 1,180 | |

| Total assets | $ | 148,924 | | | $ | 191,112 | |

| Liabilities and Stockholders’ Equity | | | | | | |

| Current liabilities: | | | | | | |

| Accounts payable | $ | 1,265 | | | $ | 943 | |

| Accrued expenses and other liabilities | | 4,359 | | | | 3,177 | |

| Current portion of operating lease liabilities | | 4,134 | | | | 3,832 | |

| Total current liabilities | | 9,758 | | | | 7,952 | |

| Operating lease liabilities, net of current portion | | 22,607 | | | | 26,187 | |

| Total liabilities | | 32,365 | | | | 34,139 | |

| | | | | | | |

| Stockholders’ equity: | | | | | | |

| Preferred stock | | — | | | | — | |

| Common stock | | 13 | | | | 13 | |

| Additional paid-in capital | | 493,940 | | | | 488,737 | |

| Accumulated other comprehensive income (loss) | | (572 | ) | | | 243 | |

| Accumulated deficit | | (376,822 | ) | | | (332,020 | ) |

| Total stockholders’ equity | | 116,559 | | | | 156,973 | |

| Total liabilities and stockholders’ equity | $ | 148,924 | | | $ | 191,112 | |

| Nautilus Biotechnology, Inc. |

| Condensed Consolidated Statements of Operations |

| Three and Nine Months Ended September 30, 2026 and 2025 (Unaudited) |

| |

| | Three Months Ended September 30, | | Nine Months Ended September 30, |

| (in thousands, except share and per share data) | 2026 | | 2025 | | 2026 | | 2025 | |

| Revenue: | | | | | | | | | | | | | |

| Grant revenue | $ | 208 | | | $ | — | | | $ | 388 | | | $ | — | |

| Service revenue | | 26 | | | | — | | | | 36 | | | | — | |

| Total revenue | | 234 | | | | — | | | | 424 | | | | — | |

| Cost of revenue: | | | | | | | | | | | | | | |

| Cost of service revenue | | 24 | | | | — | | | | 39 | | | | — | |

| Total cost of revenue | | 24 | | | | — | | | | 39 | | | | — | |

| | | | | | | | | | | | | | | |

| Operating expenses: | | | | | | | | | | | | | | |

| Research and development | | 10,176 | | | | 9,605 | | | | 29,496 | | | | 31,535 | |

| Selling, general and administrative | | 6,771 | | | | 5,867 | | | | 19,513 | | | | 19,878 | |

| Total operating expenses | | 16,947 | | | | 15,472 | | | | 49,009 | | | | 51,413 | |

| Other income (expense): | | | | | | | | | | | | | | |

| Interest income | | 1,173 | | | | 1,903 | | | | 3,922 | | | | 6,214 | |

| Other expense | | (72 | ) | | | (5 | ) | | | (100 | ) | | | (21 | ) |

| Total other income | $ | 1,101 | | | $ | 1,898 | | | $ | 3,822 | | | $ | 6,193 | |

| Net loss | $ | (15,636 | ) | | $ | (13,574 | ) | | $ | (44,802 | ) | | $ | (45,220 | ) |

| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.12 | ) | | $ | (0.11 | ) | | $ | (0.35 | ) | | $ | (0.36 | ) |

| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | | 127,238,065 | | | | 126,305,122 | | | | 127,005,067 | | | | 126,218,587 | |

| Nautilus Biotechnology, Inc. | |

| Condensed Consolidated Statements of Cash Flows | |

| Nine Months Ended September 30, 2026 and 2025 (Unaudited) | |

| | |

| | Nine Months Ended September 30, |

| (in thousands) | 2026 | | 2025 |

| Cash flows from operating activities | | | | | | | |

| Net loss | $ | (44,802 | ) | | $ | (45,220 | ) |

| Adjustments to reconcile net loss to net cash used in operating activities | | | | | | |

| Stock-based compensation expense | | 3,812 | | | | 5,373 | |

| Amortization of operating lease right-of-use assets | | 3,180 | | | | 3,529 | |

| Depreciation | | 884 | | | | 1,348 | |

| Amortization (accretion) of premiums (discounts) on securities, net | | (36 | ) | | | (1,286 | ) |

| Changes in operating assets and liabilities: | | | | | |

| Prepaid expenses and other assets | | (982 | ) | | | 149 | |

| Accounts payable | | 48 | | | | (71 | ) |

| Accrued expenses and other liabilities | | 1,066 | | | | 1,332 | |

| Operating lease liabilities | | (3,277 | ) | | | (3,475 | ) |

| Net cash used in operating activities | | (40,107 | ) | | | (38,321 | ) |

| Cash flows from investing activities | | | | | |

| Proceeds from maturities of securities | | 76,596 | | | | 74,241 | |

| Purchases of securities | | (37,494 | ) | | | (38,771 | ) |

| Purchases of property and equipment | | (2,409 | ) | | | (1,033 | ) |

| Net cash provided by investing activities | | 36,693 | | | | 34,437 | |

| Cash flows from financing activities | | | | | |

| Proceeds from exercise of stock options | | 1,233 | | | | 26 | |

| Proceeds from issuance of common stock under employee stock purchase plan | | 142 | | | | 87 | |

| Net cash provided by financing activities | | 1,375 | | | | 113 | |

| Net decrease in cash, cash equivalents and restricted cash | | (2,039 | ) | | | (3,771 | ) |

| | | | | | |

| Cash, cash equivalents and restricted cash at beginning of period | | 13,390 | | | | 28,648 | |

| Cash, cash equivalents and restricted cash at end of period | $ | 11,351 | | | $ | 24,877 | |

Stay up-to-date on all things Nautilus

Subscribe to our investor alerts

Subscribe

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... Show more

NecessaryAlways Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytics

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

Advertisement

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

Uncategorized

Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.

Reject All Save My Preferences Accept All

Powered by Cookieyes logo

Skip to content

News Release Details

Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026

Oct 15, 2026

PDF Version

SEATTLE, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the third quarter 2026 before market open on Tuesday, October 27, 2026.

The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the “Investors” section of the company website at: www.nautilus.bio.

About Nautilus Biotechnology, Inc. With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.

Media Contact [email protected]

Investor Contact [email protected]

Stay up-to-date on all things Nautilus

Subscribe to our investor alerts

Subscribe

Prompts

Nautilus Biotechnology, Inc. (ticker NAUT), listed in United States.

Company History

Date Change Detail
Mar 19, 2021 Renamed ARYA SCIENCES ACQUISITION CORP III → NAUTILUS BIOTECHNOLOGY, INC.

ETFs Holding Nautilus Biotechnology, Inc.

ETF Weight in ETF Shares Market value As of
DFUS 0.00% 7,173 $ 17.072K Nov 12, 2026
DFAS 0.00% 7,467 $ 17.771K Nov 12, 2026
DFAC 0.00% 12,424 $ 29.569K Nov 12, 2026
AVSC 0.00% 1,105 $ 2,320.50 Nov 16, 2026